TSX:SVA Archives - Spark Newswire

4 minute read

Sernova’s Cell Pouch System with Evotec’s iPSC-Derived Islet-like Clusters For Type 1 Diabetes Presented At The 4th IPITA / HSCI / JDRF Summit

April 24, 4:20 PM

Evotec's scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and

EVO

1 minute read

EF Hutton Initiates Coverage On Sernova with Buy Rating, Announces Price Target of C$5

By Benzinga Newsdesk

January 5, 5:38 AM

EF Hutton analyst Tony Butler initiates coverage on Sernova (TSX:SVA) with a Buy rating and announces Price Target of C$5.

TSX:SVA

1 minute read

News

Sernova Receives Second Tranche Equity Investment From Evotec Of $6.8M At A Price Of $2.50/Share

By Benzinga Newsdesk

September 1, 7:37 AM

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously

EVO

Feed Symbols: TSX:SVA

Sernova’s Cell Pouch System with Evotec’s iPSC-Derived Islet-like Clusters For Type 1 Diabetes Presented At The 4th IPITA / HSCI / JDRF Summit

EF Hutton Initiates Coverage On Sernova with Buy Rating, Announces Price Target of C$5

Sernova Receives Second Tranche Equity Investment From Evotec Of $6.8M At A Price Of $2.50/Share